

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華熙生物科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

APPOINTMENT AND RESIGNATION OF EXECUTIVE DIRECTORS

The Board announces that with effect from 26 August 2016:

- Ms. Liu resigned as an executive Director and a member of the Nomination Committee; and
- Mr. Gong has been appointed as an executive Director and a member of the Nomination Committee.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Bloomage BioTechnology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 26 August 2016, Ms. Liu Aihua (“**Ms. Liu**”) resigned as an executive Director and a member of the nomination committee of the Company (the “**Nomination Committee**”) in order to devote more time to her personal commitments.

Ms. Liu has confirmed that (i) she has no claims against the Company in respect of her resignation; (ii) she has no disagreement with the Board; and (iii) there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board announces that with effect from 26 August 2016, Mr. Gong Anmin (“**Mr. Gong**”) has been appointed as an executive Director and a member of the Nomination Committee.

Biographical details of Mr. Gong are set out as follows:

Mr. Gong, aged 50, joined the Group as the chief financial officer of the Company in January 2014. Mr. Gong is also the general manager of Bloomage Freda Biopharmaceutical Co., Ltd. and Shandong Bloomage Hyinc Biopharm Company Limited. Mr. Gong graduated with a bachelor’s degree in economics from the Central University of Finance and Economics in the People’s Republic of China in 1988 and completed an international MBA program organized by the China Center for Economic Research at Peking University from 2000 to 2002, and was awarded a master degree of business administration by Fordham University in the US in 2002. He had worked in several large state-owned enterprises and foreign enterprises for years, and thus had extensive experience in financial management and corporate governance.

Mr. Gong entered into a service agreement (the “Service Agreement”) with the Company for an initial term of two years with effect from 26 August 2016. Mr. Gong will hold the office until the next general meeting of the Company and he is subject to retirement and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the Service Agreement, Mr. Gong is entitled to receive an aggregate amount of director’s remuneration of HK\$200,000 per annum with such additional benefits as the Board shall in its absolute discretion deem appropriate. The remuneration of Mr. Gong was determined with reference to his responsibility and experience, the remuneration policy of the Company and prevailing market practice.

As at the date of this announcement, Mr. Gong held 968,750 shares of the Company (the “**Shares**”) and is deemed to have interests in 52,500 Shares in which his spouse is interested.

Save as disclosed herein and as at the date of this announcement, Mr. Gong (i) does not hold any other position in the Group, nor does he have any relationship with any director, senior management, substantial shareholder of the Company (as defined in the Rules Governing the Listing of Securities of the Stock Exchange (the “**Listing Rules**”) or any of their respective associates (as defined in the Listing Rules); (ii) has not held any directorship in other public companies, the securities of which are listed on any securities market in the Hong Kong Special Administrative Region of the People’s Republic of China (“**Hong Kong**”) or overseas in the past three years; and (iii) does not have, and is not deemed to have, any interests in any shares, underlying shares or debentures (as defined under Part XV of the Securities and Futures Ordinance (Chapter 571, the laws of Hong Kong)) of the Company.

Save as disclosed herein, there are no other matters relating to the appointment of Mr. Gong as an executive Director that need to be brought to the attention of the shareholders of the Company nor is there any other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (w) of the Listing Rules.

The Board would like to take this opportunity to express its gratitude to Ms. Liu for her contribution to the Company during her tenure of office and to welcome Mr. Gong for joining the Board.

By order of the Board
Bloomage BioTechnology Corporation Limited
Zhao Yan
Chairman

Hong Kong, 26 August 2016

As at the date of this announcement, the executive directors are Ms. Zhao Yan, Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua; the non-executive director is Mr. Yau Wai Yan; the independent non-executive directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Xue Zhaofeng.